ArticlePloS one2023

High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria.

Opeyemi Abudiore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.